BRPI0921541A2 - uso de menos carboidrato não-redutor, métodos para produzir e para reconstituir uma composição seca por congelamento estável, e, composição seca por congelamento estável. - Google Patents

uso de menos carboidrato não-redutor, métodos para produzir e para reconstituir uma composição seca por congelamento estável, e, composição seca por congelamento estável.

Info

Publication number
BRPI0921541A2
BRPI0921541A2 BRPI0921541A BRPI0921541A BRPI0921541A2 BR PI0921541 A2 BRPI0921541 A2 BR PI0921541A2 BR PI0921541 A BRPI0921541 A BR PI0921541A BR PI0921541 A BRPI0921541 A BR PI0921541A BR PI0921541 A2 BRPI0921541 A2 BR PI0921541A2
Authority
BR
Brazil
Prior art keywords
dried composition
stable freeze
reconstituting
producing
methods
Prior art date
Application number
BRPI0921541A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Laidler
Roderick Peter Hafner
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921541(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of BRPI0921541A2 publication Critical patent/BRPI0921541A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0921541A 2008-11-28 2009-11-27 uso de menos carboidrato não-redutor, métodos para produzir e para reconstituir uma composição seca por congelamento estável, e, composição seca por congelamento estável. BRPI0921541A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821806.7A GB0821806D0 (en) 2008-11-28 2008-11-28 Compositions with reduced dimer formation
PCT/GB2009/002767 WO2010061193A2 (en) 2008-11-28 2009-11-27 Compositions with reduced dimer formation

Publications (1)

Publication Number Publication Date
BRPI0921541A2 true BRPI0921541A2 (pt) 2016-04-26

Family

ID=40262373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921541A BRPI0921541A2 (pt) 2008-11-28 2009-11-27 uso de menos carboidrato não-redutor, métodos para produzir e para reconstituir uma composição seca por congelamento estável, e, composição seca por congelamento estável.

Country Status (20)

Country Link
US (3) US9180098B2 (https=)
EP (2) EP2373293B2 (https=)
JP (2) JP5612592B2 (https=)
KR (1) KR101669693B1 (https=)
CN (1) CN102227214B (https=)
AU (1) AU2009321358B2 (https=)
BR (1) BRPI0921541A2 (https=)
CA (1) CA2744587C (https=)
DK (1) DK2373293T3 (https=)
EA (1) EA019923B1 (https=)
ES (1) ES2427855T5 (https=)
GB (2) GB0821806D0 (https=)
HR (1) HRP20130933T1 (https=)
IL (1) IL213088A (https=)
MX (1) MX2011005530A (https=)
NZ (1) NZ593145A (https=)
PL (1) PL2373293T3 (https=)
SG (1) SG171438A1 (https=)
SI (1) SI2373293T1 (https=)
WO (1) WO2010061193A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
GB201301457D0 (en) * 2013-01-28 2013-03-13 Fluorogenics Ltd Freeze-dried composition
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
CN103656635B (zh) * 2013-12-05 2016-05-18 安徽润敏江生物科技有限公司 一种德国小蠊过敏原制剂的制备方法
PL3129001T3 (pl) * 2014-04-10 2020-06-29 Asit Biotech S.A. Preparat alergenów wolny od hsp
CA2973641A1 (en) * 2015-02-04 2016-08-11 Universitat Zurich Use of hla-b27 homodimers for cancer treatment
US20170136144A1 (en) 2015-11-12 2017-05-18 John C. Herr Compositions and methods for vas-occlusive contraception
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
AU2017230855B2 (en) 2016-03-08 2021-05-27 Universität Basel HLA-B57 open conformers
JP7010439B2 (ja) 2016-08-10 2022-01-26 ウニヴェルズィテート チューリッヒ ＭＨＣクラスＩａオープンコンフォーマー
EP4400166A3 (en) 2017-01-05 2025-01-22 Contraline, Inc. Methods for implanting and reversing stimuli-responsive implants
US12383421B2 (en) 2017-01-05 2025-08-12 Contraline, Inc. Contraceptive devices
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) * 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
JP7582939B2 (ja) 2018-11-13 2024-11-13 コントラライン，インコーポレイテッド 生体材料を送達するためのシステムおよび方法
CN116888267A (zh) * 2021-01-22 2023-10-13 先正达农作物保护股份公司 大豆工程化抗性

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (en) * 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4855407A (en) 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
JP2787162B2 (ja) * 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
ES2174822T3 (es) * 1989-11-03 2002-11-16 Immulogic Pharma Corp Una proteina felina reactiva con celulas t humanas (trfp) aislada de polvo domestico y usos para la misma.
DE69233772D1 (de) 1991-10-16 2009-11-12 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
CA2117779A1 (en) 1992-04-09 1993-10-28 Mei-Chang Kuo T cell epitopes of the major allergens from ambrosia artemisifolia
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
EP0783322A1 (en) 1994-09-02 1997-07-16 Immunologic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
GB2348808B (en) * 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
US7754686B2 (en) 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
AU2003215524A1 (en) * 2002-03-15 2003-09-29 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
WO2003093299A2 (en) 2002-05-06 2003-11-13 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
EP1685160A1 (en) 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
CN1913917B (zh) 2003-12-31 2012-02-01 正统逻辑公司 凝血酶肽衍生物的药物组合物
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
KR20070100832A (ko) 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
CN101171033A (zh) * 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
AU2006299310A1 (en) * 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation

Also Published As

Publication number Publication date
AU2009321358A1 (en) 2011-06-30
DK2373293T3 (da) 2013-10-07
CN102227214A (zh) 2011-10-26
KR101669693B1 (ko) 2016-11-09
JP2015057383A (ja) 2015-03-26
EP2373293B8 (en) 2013-09-18
CN102227214B (zh) 2015-02-18
GB201114575D0 (en) 2011-10-05
MX2011005530A (es) 2011-06-06
SI2373293T1 (sl) 2013-11-29
GB2479515B (en) 2013-05-22
EP2373293B1 (en) 2013-07-31
HK1161139A1 (en) 2012-08-24
SG171438A1 (en) 2011-07-28
EP2373293A2 (en) 2011-10-12
JP5612592B2 (ja) 2014-10-22
EP2373293B2 (en) 2016-06-01
KR20110092329A (ko) 2011-08-17
US9375470B2 (en) 2016-06-28
ES2427855T3 (es) 2013-11-04
AU2009321358B2 (en) 2015-06-18
EA019923B1 (ru) 2014-07-30
IL213088A0 (en) 2011-07-31
US20160038587A1 (en) 2016-02-11
ES2427855T5 (es) 2016-06-28
EP2649990A1 (en) 2013-10-16
WO2010061193A2 (en) 2010-06-03
WO2010061193A3 (en) 2011-06-23
US20120014978A1 (en) 2012-01-19
CA2744587A1 (en) 2010-06-03
HRP20130933T1 (hr) 2013-11-08
US9180098B2 (en) 2015-11-10
CA2744587C (en) 2020-07-14
EA201100865A1 (ru) 2011-12-30
IL213088A (en) 2017-01-31
NZ593145A (en) 2013-01-25
US20160367660A1 (en) 2016-12-22
GB0821806D0 (en) 2009-01-07
GB2479515A (en) 2011-10-12
JP5905942B2 (ja) 2016-04-20
PL2373293T3 (pl) 2013-12-31
JP2012510457A (ja) 2012-05-10

Similar Documents

Publication Publication Date Title
BRPI0921541A2 (pt) uso de menos carboidrato não-redutor, métodos para produzir e para reconstituir uma composição seca por congelamento estável, e, composição seca por congelamento estável.
BRPI0915420A2 (pt) Composições e métodos para produção de carboidratos fermentáveis em plantas
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI0919901A2 (pt) Composição nutricional líquida aquosa estável em prateleira, método para a produção de uma composição e uso de uma composição.
HRP20150107T1 (xx) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
WO2008091961A3 (en) Optical coherence tomography implementation
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
IL209593A (en) Diamino-Pyridine, Pyrimidine and Pyridazine Derivatives, Pharmaceutical Preparations Containing Them and Uses as Modulators of Histamine H4 Receptor
BRPI0811228A2 (pt) Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
BRPI1009981A2 (pt) sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula
DK3093291T3 (da) Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer
BR112012032352A2 (pt) “método para produzir ésteres de butila, métodos para produzir butanol e ésteres de butila, métodos para produzir butanol e composição”
EP2636642A4 (en) Cnt dispersion liquid, cnt compact, cnt composition, cnt assembly, and method for producing each
BRPI0917728A2 (pt) composição, uso da composição, e, método de prevenção da formação de espuma em uma composição
BRPI0911554A2 (pt) Microemulsão, processo para a preparação de uma microemulsão, e, uso da microemulsão.
BRPI0923859A2 (pt) Nanopartícula, composição, métodos para a produção das nanopartículas e de uso, e, uso de nanopartículas.
BRPI0908833A2 (pt) Composição polimérica elastomérica biodegradável, processo para preparar uma composição polimérica, e, uso da composição polimérica.
BRPI0719272A2 (pt) Composição de enzima, e, método para preparar uma composição de enzima.
BRPI0916936A8 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza das mesmas.
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI1014571A2 (pt) composições de combinação de lactona macrocíclica, vacinas e processos para produzir as mesmas
BR112012031383A2 (pt) variante de micro-organismo tendo a capacidade de produzir hidrocarbonetos, método para a preparação da variante e método para a produção de hidrocarbonetos utilizando a mesma
BRPI0917345A2 (pt) composição, e, método para produzir uma composição estabilizada.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.